Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

166 results about "2-group" patented technology

In mathematics, a 2-group, or 2-dimensional higher group, is a certain combination of group and groupoid. The 2-groups are part of a larger hierarchy of n-groups. In some of the literature, 2-groups are also called gr-categories or groupal groupoids.

Compounds for the treatment of metabolic disorders

InactiveUS20060247309A1Useful activityBiocideSenses disorderActive agentMethyl group
Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, artherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0, 1, 2, 4 or 5; q is 0 or 1; t is 0 or 1; R2 is alkyl from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by or 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloaldyl having from 3 to 6 ring carbon atoms wherein the cycloaldyl is unsubstitited or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compounds of formula (I) by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
Owner:WELLSTAT THERAPEUTICS

Compounds for the treatment of metabolic disorders

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R2 is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and 0 and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R1 is not hydrogen. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula I.
Owner:WELLSTAT THERAPEUTICS

Compounds for the treatment of metabolic disorders

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0 to 4; q is 0 or 1; t is 0 or 1; R2 is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalendy bound to the remainder of the compound of formula (I) by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
Owner:CDC INVESTMENTS LLLP

Method for preparing cholic acid conjugates

The invention provides a method for preparing a cholic acid coupler therapeutic medicine (I). The method adopts a taurine or glycinate compound as an initial material, and carries out a reaction to obtain the medicine (I) with the condensating agent of 2-chlorine-4,6-dimethoxy-1,3, 5-triazine or chloridized 4-(4,6- dimethoxy-1,3, 5-triazine-2-group)-4-methyl morpholine. The method has cheap and easily obtained raw material, gentle reaction conditions, solvent without water treatment, simple operation, high yield and friendly reaction environment. (in the formula, R1, R2, R3 represent H, alpha-OH, beta-OH, =O; R1, R2 and R3 can be the same or not the same; R represents CH2CH2SO3H, CH2COOH, CH2CH2SO3M, and CH2COOM; M represents metallic ions).
Owner:SICHUAN UNIV

Preparation method of agricultural fungicide difenoconazole

A method for preparing agricultural germicid, include the steps: 4-(4-) -2-chloro acetophenone propylene glycol generate cyclics-3-chlorine-4-(2,4-dimethyl-1,3-dioxane-2-group)benz-4'-, the reaction happens with catalyst-paratoluenesulfonic acid existing in the solvent, the density mess ratio is 5-50%. When catalyst-paratoluenesulfonic acid exists, the cyclics reacts with bromine, generating bromide-3-chlorine-4-(4-methyl-2- -1,3-dioxane-2-group)benz-4'-chlorine, the bromidereacts with 1,2,4- with potassium bromide as catalysis in acutesolvent, whose density mess ratio is 15-50%, acquiring the target compound. The invention has increased the productive efficiency of by more than 20%.
Owner:JIANGSU GENGYUN CHEM CO LTD

Compounds for the Treatment of Metabolic Disorders

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), wherein n is 1 or 2; m is 0 or 1; q is 0 or 1; t is 0 or 1; R5 is alkyl having from 1 to 3 carbon atoms; R9 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by I or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and 0 and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and X is —CH2—, Q is —OR1and R1 is methyl or ethyl; or X is —CH2CR12R13— or —CH2CH(NHAc)— wherein each of R12 and R13 is independently hydrogen or methyl, Q is OR1and R1 is hydrogen or alkyl having from 1 to 7 carbon atoms; or X is —CH2CH2— and Q is NR10R1, wherein one of R10 and R11 is hydrogen, alkyl having from 1 to 3 carbon atoms or hydroxy, and the other is hydrogen. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
Owner:WELLSTAT THERAPEUTICS

Compounds for the treatment of metabolic disorders

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 2 or 3; q is 0 or 1; t is 0 or 1; R2 is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
Owner:WELLSTAT THERAPEUTICS

Infrared optical system

An infrared optical system, which can obtain excellent image even when used under a severe condition, is easily and cheaply produced by molding. The infrared optical system, is provided with a configuration of 2 groups 2 lenses having the first lens L1 and the second lens L2 sequentially from the object side, the first lens is a convex aspheric lens of which convex surface protrudes toward the object side, and the second lens is a convex meniscus lens of which convex surface protrudes toward the object side, the infrared optical system is formed by using chalcogenide glass such that the extreme values of the surface shape of the first lens L1 and the second lens L2 are not formed at the lens surface including the outer portion of the lens effective diameter.
Owner:KK TOPCON

Organic electroluminescent device with hybrid illuminating layer

The invention is concerned with organic light-emitting devices (OLED) with complexes luminescent layer. It designs and improves the structure of organic light-emitting devices to get high efficiency and capability for the light information display and illumination field. Treat the transparent conductive glass substrate containing indium tin oxide-ITO with six layers materials. The first layer is 4, 4', 4'-tri(N-3-methyl-N- phenyl-amino)triphenylamines, i.e. m-MTDATA with 10 to 100 nm thickness, the second layer is N, N'-di(naphthyl-2-group)-N, N'-diphenylethene-di-diamino biphenyl, i.e. NPB layer with 20 to 100 nm thickness, the third layer is 4, 4'-di(carbazole -9-group)- biphenyl and tri-(8-hydroxy-quinolinato) aluminium, the forth layer is 2,9-dimethyl-4, 7-diphenylethene -1, 110-penanthroline, the fifth layer is tri-(8-hydroxy-quinolinato) aluminium, i.e. Alq3 layer, the sixth layer is alloy of magnesium and silver- Mg:Ag with 100 to 300 nm thickness.
Owner:SOUTHEAST UNIV

Compounds for the treatment of metabolic disorders

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R2 is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and 0 and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R1 is not hydrogen. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula I.
Owner:PHARMA CINQ LLC

Method for preparing candestartan

The invention relates to a method for synthesizing ridge sha tan, which uses the 2-tert-butyl ketonic oxygen amido-3-nitro benzoate (I) and N-(trityl )-5-(4'-morphine methylbiphenyll-2-group) tetrazolium (II) as raw material to do N-alkanisation reaction, protecting-released reaction, reduction reaction, ring-closed reaction and ester hydrolytic reaction. <0The protecting-released reaction can slough trityl and tert-butyl ketonic oxygen protect group in the lower aliphatic alcohol organic mixing solution.
Owner:LINHAI TIANYU PHARMA

LED (light emitting diode) light source subregion subsection transformation input driving control method and control circuit thereof

The invention relates to a semiconductor lighting application technology, and discloses an LED (light emitting diode) light source subregion subsection transformation input driving control method and a control circuit thereof.. The control circuit is provided with 3-7 groups of LED glowing units with different break-over voltages. The control method is characterized in that (1) the subsection transformation input control circuit is used for dividing the output voltage of a rectifier circuit into 2-5 regions, and the 2-6 groups of LED glowing units with high voltage break-over voltages are driven in a parallel mode, or in a serial mode or in a combined parallel and serial mode through the control circuit according to the region positions of the break-over voltages; and (2), by combining each divided region, the 1-2 groups of the LED glowing units with low break-over voltages in the LED glowing units are enabled not to light in each divided region through control circuits in a driving mode, or a parallel driving mode or a serial driving mode. The combined efficiency of an LED light source can achieve more than 90%, the power supply conversion efficiency is high, meanwhile, an electrolytic capacitor is avoided being used, and the service life is long.
Owner:郑州信泽光电科技有限公司

Synthesis of new fucose-containing carbohydrate derivatives

A method for the synthesis of a compound of formula (1) or a salt thereof, wherein A is a carbohydrate linker which is a lactosyl moiety or which consists of a lactosyl moiety and at least one monosaccharide unit selected from the group consisting of: glucose, galactose, N-acetylglucosamine, fucose and N-acetyl neuraminic acid; and wherein R1 is one of the following anomeric protecting groups: a) -OR2, wherein R2 is a protecting group removable by catalytic hydrogenolysis; b) -SR3, wherein R3 is an optionally substituted alkyl, an optionally substituted aryl or an optionally substituted benzyl; c) -NH- C(R")=C(R')2, wherein each R' independently is one of the following electron withdrawing groups: -CN, -COOH, -COO-alkyl, -CO-alkyl, -CONH2, -CONH- alkyl or -CON(alkyl)2, or wherein the two R'-groups are linked together and form -CO-(CH2)2-4-CO- and thus form, together with the carbon atom to which they are attached, a 5-7 membered cycloalkan-1,3-dione, in which dione any of the methylene groups is optionally substituted with 1 or 2 alkyl groups, and R" is H or alkyl, in which a fucosyl donor of formula (2) wherein X is selected from the group consisting of: a guanosine diphosphatyl moiety, a lactose moiety, azide, fluoride, optionally substituted phenoxy-, optionally substituted pyridinyloxy-, optionally substituted 3-oxo-furanyloxy- of formula (A), optionally substituted 1,3,5-triazinyloxy- of formula (B), 4-methylumbelliferyloxy-group of formula (C), and a group of formula (D) wherein Ra is independently H or alkyl, or two vicinal Ra groups represent a=C(Rb)2 group, wherein Rb is independently H or alkyl, Rc is independently selected from the group consisting of alkoxy, amino, alkylamino and dialkylamino, Rd is selected from the group consisting of H, alkyl and -C(=O)Re, wherein Re is OH, alkoxy, amino, alkylamino, dialkylamino, hydrazino, alkylhydrazino, dialkylhydrazino or trialkylhydrazino, is reacted with an acceptor of formula H-A-R1 or a salt thereof, wherein A and R1 are as defined above, under the catalysis of an enzyme capable of transferring fucose. A compound of formula 1', its use in manufacture of human milk oligosaccharides, a method of manufacture of human milk oligosaccharides, and a fucosyl donor are also provided.
Owner:GLYCOM AS (DK)

Method for preparing iron-nickel-phosphorus chemical plating

The invention belongs to the technical field of chemical deposition, in particular to a new method for preparing an iron-nickel-phosphorus chemical plating. The plating can be widely used in (micro) electronic industry and space navigation and general projects. In the method, a compound complex system consisting of sodium potassium tartrate tetrahydrate, trisodium citrate, two organic mixed additives having N(CH2COOH)2 groups and ammonia water is used for controlling Fe<2+> and Ni<2+> concentrations, reducing the reduction speed of nickel and improving the reduction speed of iron so as to improve the iron content of the plating; the compound complex system can be complexed with impurity ions to improve the containable metal impurity ion concentration of the solution. The method is particularly suitable for preparing high-iron content iron-nickel-phosphorus chemical plating on silicon chips or copper surfaces. The plating on a silicon chip surface comprises 0 to 50 percent (controllable) of iron atoms, 2 to 18 percent of phosphorus atoms and the balance of nickel; and the plating on a copper surface contains 0 to 90 percent (controllable) of iron atoms, 2 to 16 percent of phosphorus atoms and the balance of nickel.
Owner:INST OF METAL RESEARCH - CHINESE ACAD OF SCI

Fluorooxyalkylene group-containing polymer composition, surface treatment agent containing the composition, and article and optical article treated with the surface treatment agent

There is disclosed a fluorooxyalkylene group-containing polymer composition represented by the following average composition formula (1). In the formula, the ratio of the Rf 2 group is 30 to 75 mole%, relative to a total of all of the terminal groups in the composition, and the fluorooxyalkylene group-containing polymer composition includes a one-terminal hydrolyzable silyl group-containing polymer and a both-terminal hydrolyzable silyl group-containing polymer, A-Rf 1 -B (1) wherein Rf 1 represents a divalent linear fluorooxyalkylene group, A and B represent groups represented by an Rf 2 group or a group represented by the formula (2), Z represents a divalent to heptavalent linking group having a silalkylene structure or a silarylene structure but no siloxane bond, X represents a hydrolyzable group, and Y is a linking group represented by C c H 2c or C 2 H 4 -C r F 2r -C 2 H 4 . As a result, there is provided a fluorooxyalkylene group-containing polymer composition of forming a coated film which is excellent in water- and oil-repellency, low dynamic friction coefficient, releasing property, property of wiping off stain and excellent in abrasion resistance, adhesiveness to a substrate and alkaline resistance, and to provide a surface treatment agent, an article and an optical article.A-Rf1-B (1).
Owner:SHIN ETSU CHEM IND CO LTD

Combined type tea water removing machine

InactiveCN104222349APrevents moisture loss problemsPrevents tea from being crushedPre-extraction tea treatmentThermal insulationReducer
The invention discloses a combined type tea water removing machine. The combined type tea water removing machine comprises a rack body, a thermal insulation shell, a rotary roller and a guide blade, the thermal insulation shell is fixed on the rack body, the rotary roller is inserted in the thermal insulation shell, idler wheels are firmly arranged at two ends of the rotary roller, the rack body is provided with 2 groups of bearing idler wheels, the bearing idler wheels are arranged below the idler wheels and connected with the idler wheels in a rolling mode, the rack body is further provided with an idler wheel drive motor, and the idler wheel drive motor is connected with the rotating shaft of one bearing idler wheel through a speed reducer; the guide blade is welded on the inner wall of the rotary roller, a combined type fire nozzle is arranged between the thermal insulation shell and the rotary roller, and a steam heating device is arranged in the rotary roller. The combined type tea water removing machine is capable of realizing water removing stage by stage so that tea can be roasted under different temperatures in the same equipment, and the tea obtains the best green moving effect.
Owner:张家界西莲茶业有限责任公司

Method for preparing sartan drug main ring 5-(4'-formyl biphenyl-2-group)-1H-tetrazole treating hypertension

The invention belongs to drug synthesis, particularly relates to the main ring of Sartan drug for the treatment of the hypertension i.e. 5-(4'-formyl biphenyl-2-base)-1H-tetrazole. The preparation method comprises the following procedures, bromination, esterification, cyclization, hydrolysis and oxidation. Utilizing the triethylamine hydrochloride to serve as the catalyst, the method of the invention inhibits the side reaction, promotes the purity and the yield of the product, avoids the residue of the poisonous matter in the drug intermediate, reduces the waste discharge, realizes the clean production and protects the environment.
Owner:NANTONG SHIMEIKANG PHARMA CHEM

Compounds for the Treatment of Metabolic Disorders

InactiveUS20080306165A1BiocideSenses disorderCystic ovaryMethyl group
Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, poly-cystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; one of R3 and R4 is hydrogen or hydroxy and the other is hydrogen; or R3 and R4 together are ═O; R5 is hydrogen or alkyl having one, two, three, four or five carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon. Alternatively, the. agent can be a pharmaceutically acceptable salt of the compound of Formula I.
Owner:WELLSTAT THERAPEUTICS

Fluorocarbon surface active agent and preparation method thereof

The invention relates to a fluorocarbon surface active agent containing CF3CF2CF2C(CF3)2 groups and a preparation method thereof. The preparation method comprises the following steps: carrying out nucleophilic substitution on perfluor-2-methyl-2-amylene as an initial raw material and benzyl bromine to prepare a fluorine-containing middle body carboxylic acid, and neutralizing the carboxylic acid and an alkaline solution to obtain an anionic fluorocarbon surface active agent; blending the carboxylic acid and amine to prepare a fluorine-containing middle body amide, and reacting the amide with alkyl halide, sodium chloroacetate or biphenyl benzylidene chloride to obtain a quaternary ammonium salt cation fluorocarbon surface active agent, a glycine betaine amphoteric fluorocarbon surface active agent or a double fluorocarbon surface active agent correspondingly. The method provided by the invention has the advantages that the raw materials are easily available, the technology is simple, the price is low, the repeatability is good, and the surface tension property of the product is good.
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI +1

Circuit used for realizing physical unclonable function and corresponding operation method

The invention relates to a circuit used for realizing a physical unclonable function. The circuit comprises n pieces of oscillators of which the time delay paths are configurable, wherein n is an even number; the oscillators independently have the frequencies of f0, f1...fn-2 and fn-1; n pieces of oscillators are divided into n / 2 groups, and each group comprises two oscillators; and each oscillator comprises m pieces of time delay unit groups, and each time delay unit group comprises at least two time delay units. The circuit is configured as follows: receiving challenges; selecting the time delay unit to form the time delay path; obtaining the frequency difference value of two oscillators in each group, and carrying out evaluation on the frequency difference value; and carrying out accumulation on the frequency difference value, and obtaining a bit response according to an accumulated sum. In addition, the invention also relates to a method for operating the circuit.
Owner:SHANGHAI HUAHONG INTEGRATED CIRCUIT

Joint user grouping and power distribution method and base station using same

The invention provides a joint user grouping and power distribution method and a base station using the method, applicable to a collaborative non-orthogonal multiple access system. The method providedby the invention comprises the following steps of sorting user devices according to K channel gains between the base station and the K user devices, and building a strong user candidate group including K / 2 user devices and a weak user candidate group including K / 2 user devices; pairing each one in the strong user candidate group with the one in the weak user candidate group, and meanwhile computing power distribution coefficients corresponding to the two user devices in each paired combination to divide the K user devices into K / 2 groups; and according to the power distribution coefficients corresponding to the K / 2 groups, transmitting messages to the K user devices.
Owner:王晋良

Inertial confinement and induction drilling device with PDC drill bit

Disclosed is an inertial confinement and induction drilling device with a PDC drill bit. A planetary frame is installed on the outer circumferential surface of an input shaft of the sun wheel in a sleeving mode, and a small sliding bushing is installed on the circumferential surface of the input shaft of the sun wheel in a sleeving mode; four planetary gear shafts are all arranged on the surface of the planetary frame, 8 planetary gears are divided into 2 groups and axially arranged on the planetary gear shafts in a sleeving mode, and one group of planetary gears are close to the drill-collar connecting end of the input shaft of the sun wheel; the end surfaces of the first group of planetary gears are fitted with the inner end surfaces of steps at one end of the input shaft of the sun wheel through end-surface pressure bearings. An output shaft of the planetary frame is installed on the outer circumferential surface of the input shaft of the sun wheel, so that the inner end surface of the output shaft of the planetary frame is fitted with the outer end surface of the planetary frame. The inertial confinement and induction drilling device with the PDC drill bit is completed on the basis of a planetary-wheel reducer structure, and has the advantages that the impact is stable and continuous, the durability is guaranteed, the quality of drilling holes is ensured, and the energy consumption is low.
Owner:NORTHWESTERN POLYTECHNICAL UNIV +1

Surface active agent containing hexafluoropropylene tripolymer group and preparation method thereof

The invention discloses a surface active agent containing a hexafluoropropylene tripolymer group and a preparation method thereof. The hexafluoropropylene tripolymer is a fluorine-containing precursor material, and the surface active agent is prepared by taking a benzene ring as a rigid connecting chain. The surface active agent comprises a cation series, an amine oxide series and an anion series which are respectively in the form of 4-perfluoro-(4-methyl-3-isopropyl-2-amylene-2-group) oxygen benzyl ammonium cation, 4-perfluoro-(4-methyl-3-isopropyl-2-amylene-2-group) oxygen benzyl amine oxide and 4-perfluoro-(4-methyl-3-isopropyl-2-amylene-2-group) oxygen benzyl sulphonate (sulfate). The surface active agent disclosed by the invention has the advantages of no harm characteristic of a lasting organic pollutant, high surface activity, low critical micelle concentration and high heat stability; the fluorine-containing surface active agent disclosed by the invention has potential application value in special application fields of tertiary oil extraction, fluorine-containing polymer polymerization, and the like, and the fields of common surface active agents and the like.
Owner:HUAZHONG NORMAL UNIV

Amino sugar thiazole derivative as well as synthetic method and application thereof

The invention discloses an amino sugar thiazole derivative as well as a synthetic method thereof. When synthesis is carried out, glucosamine hydrochloride is taken as a raw material, and benzyl ether protection is carried out on hydroxy, so that the selective reaction of amino is realized, a novel intermediate glycosyl thiourea-N-(1,3,4,6-tetra-0-benzyl-2-deoxygenation- beta-D-glucopyranose-2-group) thiocarbamide is synthesized, and glycosyl thiazole-N-(1,3,4,6-tetra-0-benzyl-beta-D-glucopyranose-2-group)-2-amido-4-substituted thiazole is synthesized by cyclizing the novel intermediate glycosyl thiourea-N-(1,3,4,6-tetra-0-benzyl-2-deoxygenation beta-D-glucopyranose-2-group) thiocarbamide with 1-bromine-2-substituted ethyl ketone. The synthetic method disclosed by the invention has the advantages of easiness and safety for operation, wide application scope, low cost of the raw material, easiness for raw material obtaining, easiness and convenience for post-processing and high yield, is a fast high-efficiency synthetic method and has a wide application prospect on the aspect of preparing an acetylcholinesterase resistant drug because the synthesized compound has high inhibiting effect on acetylcholinesterase.
Owner:HUAIHAI INST OF TECH

Stretch yarn special crepe shell fabric

InactiveCN1676707AIncrease elasticityExcellent stretch elasticityWoven fabricsYarnFiber
This is a kind of spring filament specially crepe plus material, referring to a kind of plus material, especially about a kind of true silk of a new structure. The meridian is heavy twist silk filature(3 / 20 / 22D21T / 2S,2Z silk filature). The latitude line uses 2 groups of material, one group(first parallel) is 2 / 20 / 22D10T / S,Z medium silk filature and the other(second parallel) is double composite filament of true silk / new LYCRA bag filament-wound. --- [(cocoon fiber 20 / 22Df3 / RAKA 20Df1S1700BS)*2]1.9T / S. This product can change the shape of the stereo flower pattern on the base of keeping excellent elastic behavior. The flower pattern can be very emergent or smooth. So we have got the skill of infinitely changing the grains of the stereo flower pattern of fabrics.
Owner:周文峰

Preparation method for dexlansoprazole

The invention discloses a preparation method for dexlansoprazole, belonging to the field of organic synthesis. The method comprises the following steps: (1) carrying out reaction on 2-hydroxymethyl-3-methyl-4-(2,2,2-trifluoro ethyoxyl) pyridine and thionyl chloride, and compounding 2-chloromethyl-3-methyl-4-(2,2,2-trifluoro ethyoxyl) pyridine; (2) putting 2-chloromethyl-3-methyl-4-(2,2,2-trifluoro ethyoxyl) pyridine acquired in the step (1) and 2-sulfydryl-1H-benzimidazole into an aqueous liquid, and then adding a phase transfer catalyst and sodium hydroxide, thereby acquiring 2-[[3-methyl-4-(2,2,2-trifluoro ethyoxyl) pyridine-2-group] methylmercapto]-1H-benzimidazole; (3) taking L-ethyl tartrate as a chiral assistant agent, titanium isopropoxide and diisopropylethylamine as a catalyst and cumyl hydroperoxide as an oxidizing agent and reacting with 2-[[3-methyl-4-(2,2,2-trifluoro ethyoxyl) pyridine-2-group] methylmercapto]-1H-benzimidazole acquired in the step (2) at low temperature, thereby acquiring dexlansoprazole. The preparation method for dexlansoprazole disclosed by the invention is simple and efficient, is capable of obviously shortening the reaction time under the condition of guaranteeing the product yield and is capable of improving the product quality.
Owner:石家庄市度智医药科技有限公司

Sealing agent for liquid crystal dropping methods, vertically conducting material, and liquid crystal display element

The present invention provides a sealing agent for liquid crystal dropping methods, which has excellent photocurability and is capable of suppressing liquid crystal contamination. The present invention also provides a vertically conducting material and a liquid crystal display element, each of which is produced using the sealing agent for liquid crystal dropping methods. The present invention is a sealing agent for liquid crystal dropping methods, which contains a curable resin and a photopolymerization initiator, and wherein the photopolymerization initiator contains a compound represented by formula (1) and an oxime ester compound so that the weight ratio of the compound represented by formula (1) to the oxime ester compound is from 1:3 to 1:100. In formula (1), each of R1 and R2 represents a hydrogen atom or an -NR3 2 group, and R1 and / or R2 represents an -NR3 2 group; and each R3 represents a hydrogen atom or an alkyl group having 1-4 carbon atoms. In this connection, the R3 moieties may be the same as or different from each other.
Owner:SEKISUI CHEM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products